These are in line with those for IDFS for pertuzumab in adjuvant treatment of HER2-positive breast cancer patients (23) and of higher magnitude than those reported by NICE (24) to approve the use of bisphosphonates in postmenopausal patients in the United Kingdom on the basis of the EBCTCG meta-analysis (3). This evidence concerns the gene ERBB2 and breast carcinoma.